| Aug 11 |
Wall Street Breakfast: The Week Ahead
|
| Aug 10 |
Cassava Sciences, Inc. (NASDAQ:SAVA): Is Breakeven Near?
|
| Aug 8 |
Cassava Sciences: New CEO, Same Old Problems
|
| Aug 8 |
Cassava Sciences Q2 Earnings Review: So Many Questions, So Few Answers
|
| Aug 8 |
Cassava Sciences, Inc. (SAVA) Q2 2024 Earnings Call Transcript
|
| Aug 8 |
Cassava Sciences estimates $40M loss contingency to resolve SEC simufilam probe
|
| Aug 8 |
Cassava Sciences GAAP EPS of $0.13
|
| Aug 8 |
Cassava Sciences Reports Q2 2024 Financial Results and Operational Updates
|
| Aug 5 |
Biotech firm drops defamation suit against short-sellers after researcher charged
|
| Aug 5 |
Cassava Sciences Mourns the Death of Board Member Sanford “Sandy” Robertson
|
